<DOC>
	<DOCNO>NCT01875237</DOCNO>
	<brief_summary>The goal clinical research study learn give genetically change immune cell , call T-cells , chemotherapy improve response stem cell transplant . The safety treatment also study . The process change DNA ( genetic material cell ) T-cells call `` gene transfer . '' Researchers want learn genetically-changed T-cells effective attacking cancer cell patient leukemia , MDS , lymphoma , Hodgkin disease , MM , receive allogeneic stem cell transplant . The chemotherapy give study fludarabine , melphalan , alemtuzumab . These drug design stop growth cancer cell , may cause cancer cell die . This chemotherapy also design block body 's ability reject donor 's stem cell . Researchers also want learn give AP1903 help symptoms graft-versus-host disease ( GvHD ) may occur T-cell infusion . GvHD occur donor cell attack cell person receive stem cell transplant .</brief_summary>
	<brief_title>Donor Lymphocyte Infusion ( DLI ) T-cells Genetically Modified With iCasp9 Suicide Gene</brief_title>
	<detailed_description>Gene Transfer : Gene transfer involve draw blood transplant donor , separate T-cells use machine . Researchers perform gene transfer change T-cells ' DNA , inject change T-cells body patient receive transplant . Study Drug Administration : You receive fludarabine , melphalan , alemtuzumab kill cancer cell help prevent body reject stem cell . The day receive stem cell call Day 0 . The day receive stem cell call minus day . The day receive stem cell call plus day . On Day -7 , admit hospital give fluid vein hydrate . On Days -6 -3 , receive fludarabine vein 1 hour day . On Day -2 , receive melphalan vein 30 minute . On Day -1 , receive alemtuzumab vein 2 hour . On Day 0 , receive stem cell transplant cell infusion vein . After transplant , receive tacrolimus methotrexate . At first , receive tacrolimus continuous ( nonstop ) infusion able take mouth . You take tacrolimus mouth 2 time day 3 week doctor tell taper ( gradually stop take ) . On Days +1 , +3 , +6 , +11 , receive methotrexate vein 30 minute . You receive filgrastim injection skin 1 time day , start 1 week transplant , blood cell level return normal . Filgrastim design help growth white blood cell . Between Day +56 +64 , stable medical condition develop GvHD , receive donor lymphocyte infusion contain genetically modify T-cells vein 10-30 minute . You receive Benadryl ( diphenhydramine ) vein 15 minute Tylenol mouth infusion low risk allergic reaction . If doctor think need due medical problem , T-cell infusion may postpone 6 month transplant . If develop symptom GvHD T-cell infusion , must return clinic within 72 hour . Most case GVHD occur within 60 day T-cell infusion . If GvHD , receive AP1903 vein possibly steroid mouth vein . If doctor think need , may receive one dose AP1903 vein 24-72 hour first dose . If GvHD return first treatment doctor think need , may receive AP1903 vein steroids mouth vein . Blood ( 2 tablespoon time ) drawn 3 hour receive AP1903 , 2 hour AP1903 infusion , 24 hour AP1903 infusion check level genetically modify T-cells . You come clinic every day next 3 day additional 3 day second dose AP1903 , give . In addition , come clinic Days +7 , +14 , +28 , +42 +56 receive AP1903 . If symptom improve receive AP1903 , give standard drug GvHD . Study Tests : After stem cell transplant T-cell infusion , follow test procedure find eligible T-cell infusion : - You physical exam . - You check possible reaction treatment , include GvHD . - Blood ( 4 tablespoon ) draw routine test , check liver kidney function , chimerism study ( determination donor recipient cell ) , check cytomegalovirus ( CMV ) . - If doctor think need , bone marrow aspiration biopsy perform check status disease . To collect bone marrow aspiration/biopsy , area hip numb anesthetic , small amount bone marrow bone withdrawn large needle . About twice week 2 month T-cell infusion , 6 12 month stem cell transplant : - You physical exam , include measurement height , weight vital sign . - Your medical history record . - You check possible reaction treatment , include GvHD . - Blood ( 4 tablespoon ) draw routine test , check liver kidney function , check CMV infection . Part blood may use chimerism study , doctor think need . - If doctor think need , may bone marrow aspiration biopsy perform check status disease chimerism study . If doctor think need , test procedure may repeat frequently different time point study . Immune System T-cell Level Tests : If possible , blood ( 3 tablespoon ) draw check status disease immune system function : - 4 hour T-cell infusion , - week 1 month T-cell infusion , - 6 week 2 , 3 , 6 , 9 , 12 month T-cell infusion . Â°Part blood sample use check HAMA 3 month T-cell infusion . Part blood drawn test check level function infuse T-cells . At 3 month T-cell infusion , blood ( 1 teaspoon ) drawn check HAMA . Questionnaires : You complete quality life questionnaire take 5-10 minute time : - When enroll study - At time T-cell infusion - If develop symptom GvHD T-cell infusion receive AP1903 , complete questionnaire receive AP1903 , 7 14 day receive AP1903 . - If develop symptom GvHD , complete questionnaire 1 month T-cell infusion . Length Treatment : You study 1-year follow-up visit . You take study early : - enough donor cell could collect - eligible receive T-cell infusion - graft failure ( donor cell `` take '' ) - disease come back need another treatment - unable keep appointment - return clinic within 72 hour symptom GvHD - study doctor think best interest If take study , receive standard care treatment . Long-Term Follow-Up : For safety reason , U.S. Food Drug Administration ( FDA ) require patient receive infusion stem cell treat gene transfer procedure must long-term follow-up yearly least 15 year receive gene transfer . You blood test perform check make sure type infection call replication-competent retrovirus ( RCR ) . For test , blood ( 4 teaspoon time ) drawn 1 , 3 , 6 month T-cell infusion , every 6 month 5 year , year 10 year . If RCR test result first year T-cell infusion show RCR infection , rest leftover blood sample ( left RCR test Years 2-15 ) store Bellicum safety reason . This researcher study change blood ( related RCR ) may arise Years 2-15 . You ask sign separate consent form long-term follow-up study , Protocol 2006-0676 . If reason unable receive genetically modify cell , enrol long-term follow-up study . This investigational study . The gene transfer infusion genetically-changed T-cells drug , AP1903 , FDA approve commercially available use type disease . They currently use research purpose . Fludarabine , melphalan , alemtuzumab commercially available FDA approve . Up 35 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Suicide</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>1 . Age &gt; /= 18 year &lt; /= 65 year . 2 . One following : . Acute leukemia past first remission , first subsequent relapse , second great remission . Patients first remission intermediate high cytogenetic risk factor flt3 mutation . Patients relapse disease . Patients primary induction failure relapse eligible &lt; 10 % bone marrow blast , circulate blast . b. Myelodysplastic syndrome intermediate high risk IPSS score , treatment related MDS . c. CML resistant tyrosine kinase treatment first subsequent chronic phase transformation accelerate phase blast crisis . 3 . 2 ( continue ) : d. CLL , Lymphoma Hodgkin 's disease fail achieve remission recur follow initial chemotherapy . Patients must least PR salvage therapy , low bulk untreated relapse ( &lt; 2 cm large mass ) . e. Multiple myeloma relapse progress achieve partial response salvage chemotherapy . 4 . Patients must one follow donor type identify willing donate peripheral blood : . Related donor , 8/8 HLAmatched HLAA , B , C DR match , b . Matched Unrelated Donor ( MUD ) , 8/8 HLAmatched HLA A , B , C DRB1 use allele level typing . 5 . Performance score least 80 % Karnofsky . 6 . Adequate major organ system function demonstrate : a. Creatinine &lt; 1.8 mg/dl ( creatinine clearance &gt; 40 ml/min ) b. Bilirubin &lt; 1.5 mg/dl except Gilbert 's disease c. ALT &lt; 300 IU/ml d. Left ventricular ejection fraction equal great 40 % . e. Pulmonary function test ( PFT ) demonstrate diffusion capacity least 50 % predict , correct hemoglobin . 7 . Patient patient 's legal representative , able sign inform consent . 8 . Patient patient 's legal representative , parent ( ) guardian able provide write informed consent longterm followup gene therapy study 20060676 . 9 . The patient need available evaluation within 72 hour symptom GVHD , occur within 60 day plan donor lymphocyte infusion . 1 . Uncontrolled active infection . 2 . Positive Beta HCG test woman child bear potential , define postmenopausal 12 month previous surgical sterilization . 3 . Women child bear potential willing use effective contraceptive measure study . 4 . Men willing use effective contraception method study . 5 . Known sensitivity product administer study . 6 . HIV seropositive . 7 . Prior allogeneic transplant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Myeloma</keyword>
	<keyword>Myeloproliferative Diseases</keyword>
	<keyword>Myelodysplastic syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Hodgkin disease</keyword>
	<keyword>Multiple myeloma</keyword>
	<keyword>MM</keyword>
	<keyword>Transplant donor</keyword>
	<keyword>T-cells</keyword>
	<keyword>G-versus-host disease</keyword>
	<keyword>GvHD</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Filgrastim</keyword>
	<keyword>Neupogen</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Fludarabine phosphate</keyword>
	<keyword>Fludara</keyword>
	<keyword>Melphalan</keyword>
	<keyword>Alkeran</keyword>
	<keyword>Alemtuzumab</keyword>
	<keyword>CAMPATH-1H</keyword>
	<keyword>Campath</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Prograf</keyword>
	<keyword>Mini-methotrexate</keyword>
	<keyword>AP 1903</keyword>
	<keyword>Methylprednisolone</keyword>
	<keyword>Depo-Medrol</keyword>
	<keyword>Medrol</keyword>
	<keyword>Solu-Medrol</keyword>
	<keyword>Stem cell infusion</keyword>
	<keyword>Donor lymphocyte infusion</keyword>
	<keyword>DLI</keyword>
	<keyword>Questionnaire</keyword>
	<keyword>Survey</keyword>
</DOC>